Jonathan Strosberg, MD, medical oncologist, is Section Head of the Neuroendocrine Tumor Division and Chair of the Gastrointestinal Department Research Program at the Moffitt Cancer Center in Tampa, Florida. His clinical interest centers on neuroendocrine cancer, specifically carcinoid tumors and pancreatic endocrine (islet cell) tumors. His research focus includes the development of novel biomarker-driven therapeutic treatments. Collaborative research has led to the identification of new molecular prognostic markers associated with malignant progression of pancreatic neuroendocrine tumors. His data on the treatment of metastatic pancreatic endocrine tumors with the novel combination of capecitabine and temozolomide was internationally recognized.
Dr. Strosberg has published over 150 articles on the diagnosis and management of neuroendocrine malignancies in many prestigious medical journals with first-author publications in the New England Journal of Medicine, The Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, and other major journals. Dr. Strosberg is the current President of the North American Neuroendocrine Tumor Society (NANETS), and serves on the Neuroendocrine Guidelines Committee of the National Comprehensive Cancer Network (NCCN) and the Neuroendocrine Task Force of the National Cancer Institute (NCI).
Click here to read about the clinical trials in which Dr. Strosberg is involved as well as for links to his research publications.
